Insider · CIK 0001665133
Carole Nuechterlein
Files at ALGS (Aligos Therapeutics, Inc.). First filing -, latest -.
In brief
Carole Nuechterlein files SEC Form 4 as director at ALGS (Aligos Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Carole Nuechterlein has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 2 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2026 | ALGS Aligos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 29, 2026 |
| Jun 25, 2025 | ALGS Aligos Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +5,860 | $0.00 | $0 | 5,860 | Jun 26, 2025 |
Questions about Carole Nuechterlein
Answered from the filings on this page, as of the latest one.
Is Carole Nuechterlein buying or selling?
Carole Nuechterlein has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Carole Nuechterlein's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Carole Nuechterlein has 0.
Where does Carole Nuechterlein file Form 4?
Carole Nuechterlein has filed Form 4 at ALGS (Aligos Therapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.